Active substance
Desvenlafaxine
- SFDA 4
- US FDA 16
- EMA 1
- Health Canada 20
- US price lines 8
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DAVLEX | 50 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 74.55 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| PRISTIQ 50MG EXTENDED RELEASE TABLETS | 50 mg | Prolonged-release tablet · Oral use | 30 Bottle | SAR 78.50 | NCE · Prescription | PFIZER INC | Valid |
| Varenya | 50 mg | Extended-release tablet · Oral use | 30 Blister | SAR 51.05 | Generic · Prescription | Boston Oncology Arabia | Valid |
| Varenya | 100 mg | Extended-release tablet · Oral use | 30 Blister | SAR 75.40 | Generic · Prescription | Boston Oncology Arabia | Valid |
Indications — CHI Daman Drug Formulary
DEPRESSION; MENOPAUSE; MENSTRUAL DISORDERS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PRISTIQ | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | PF PRISM CV | Prescription | 29 Feb 2008 |
| DESVENLAFAXINE | 50MG; 100MG | tablet, extended release · oral | ALEMBIC PHARMS LTD | Prescription | 4 Mar 2013 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | ALEMBIC | Prescription | 29 Jun 2015 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | RUBICON RESEARCH | Prescription | 29 Jun 2015 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | LUPIN | Prescription | 29 Jun 2015 |
| DESVENLAFAXINE SUCCINATE | EQ 100MG BASE; EQ 25MG BASE; EQ 50MG BASE | tablet, extended release · oral | HIKMA PHARMS | Prescription | 16 Feb 2016 |
| DESVENLAFAXINE SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | ACTAVIS LABS FL | Prescription | 29 Jul 2016 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 11 Oct 2017 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE | tablet, extended release · oral | YICHANG HUMANWELL | Prescription | 1 Oct 2018 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | PLATINUM | Prescription | 7 May 2019 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | MACLEODS PHARMS | Prescription | 15 Jan 2025 |
| DESVENLAFAXINE SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | YICHANG HUMANWELL | Prescription | 10 Mar 2026 |
| KHEDEZLA | 50MG; 100MG | tablet, extended release · oral | OSMOTICA PHARM CORP | Discontinued | 10 Jul 2013 |
| DESVENLAFAXINE | EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | TEVA PHARMS USA | Discontinued | 11 Oct 2013 |
| DESVENLAFAXINE | EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | SUN PHARM | Discontinued | 28 Jan 2014 |
| DESVENLAFAXINE SUCCINATE | EQ 50MG BASE; EQ 100MG BASE | tablet, extended release · oral | PHARMOBEDIENT | Discontinued | 29 Jun 2015 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-DESVENLAFAXINE | 02525615 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | ANGITA PHARMA INC. |
| AG-DESVENLAFAXINE | 02525623 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | ANGITA PHARMA INC. |
| APO-DESVENLAFAXINE | 02466988 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-DESVENLAFAXINE | 02466996 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| DESVENLAFAXINE | 02535106 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANIS HEALTH INC |
| DESVENLAFAXINE | 02535114 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANIS HEALTH INC |
| DESVENLAFAXINE | 02543672 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| DESVENLAFAXINE | 02543680 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| DESVENLAFAXINE | 02554968 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | SIVEM PHARMACEUTICALS ULC |
| DESVENLAFAXINE | 02554976 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | SIVEM PHARMACEUTICALS ULC |
| JAMP DESVENLAFAXINE | 02495139 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| JAMP DESVENLAFAXINE | 02495147 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| PRISTIQ | 02321092 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| PRISTIQ | 02321106 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| SANDOZ DESVENLAFAXINE | 02538415 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ DESVENLAFAXINE | 02538423 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SPC-DESVENLAFAXINE | 02532158 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| SPC-DESVENLAFAXINE | 02532166 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TEVA-DESVENLAFAXINE | 02458217 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-DESVENLAFAXINE | 02458225 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DESVENLAFAXINE ER 100 MG TAB | $3.81401 | per EA | 23 Sep 2026 |
| US NADAC | DESVENLAFAXINE ER 50 MG TAB | $3.75523 | per EA | 23 Sep 2026 |
| US NADAC | DESVENLAFAXINE SUCCNT ER 100 MG | $0.4136 | per EA | 23 Sep 2026 |
| US NADAC | DESVENLAFAXINE SUCCNT ER 25 MG | $0.39851 | per EA | 23 Sep 2026 |
| US NADAC | DESVENLAFAXINE SUCCNT ER 50 MG | $0.39649 | per EA | 23 Sep 2026 |
| US NADAC | PRISTIQ ER 100 MG TABLET | $13.93397 | per EA | 23 Sep 2026 |
| US NADAC | PRISTIQ ER 25 MG TABLET | $13.973 | per EA | 23 Sep 2026 |
| US NADAC | PRISTIQ ER 50 MG TABLET | $13.96336 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Aug 2023 DESVENLAFAXINE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 DESVENLAFAXINE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 PRISTIQ — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Sep 2021 KHEDEZLA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 1 Oct 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jun 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.